Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'
Executive Summary
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.